Azaya Therapeutics Inc. said Tuesday that the first patient has been enrolled in a pivotal study to gauge the effectiveness of a new formulation of the company’s drug docetaxel. The Phase 1 clinical study is being managed by ResearchPoint and is being conducted at South Texas Accelerated Research Therapeutics (START) in San Antonio and The Mary Crowley Cancer Research Center in Dallas. The two companies want to enroll 24 patients over the next 12 to 15 months. Patients will be given the investigational drug compound ATI-1123, which has the same active ingredient as Azaya’s FDA-approved drug Taxotere (docetaxel). Azaya officials say the new formulation has the potential of being a more effective cancer drug than the original formulation of docetaxel as demonstrated in preclinical trials. The goal of this phase 1 study is to determine the maximum tolerated dosage that can be given to patients as well as to determine the safety and effects the drug has on the body. Azaya is a San Antonio-based pharmaceutical company that is working to develop safe and effective cancer treatments. ResearchPoint is an Austin-based contract research organization.
|
•
del.icio.us
digg
facebook
E-mail this release to a friend (requires login).